Delaney Dennis R Acquires 3,834 Shares of Johnson & Johnson (JNJ)

Delaney Dennis R raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 18.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,304 shares of the company’s stock after purchasing an additional 3,834 shares during the quarter. Johnson & Johnson accounts for approximately 4.5% of Delaney Dennis R’s investment portfolio, making the stock its 2nd largest holding. Delaney Dennis R’s holdings in Johnson & Johnson were worth $3,395,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in JNJ. Bank of New York Mellon Corp increased its stake in shares of Johnson & Johnson by 0.4% during the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after buying an additional 130,437 shares during the period. Legal & General Group Plc increased its stake in shares of Johnson & Johnson by 1.7% during the third quarter. Legal & General Group Plc now owns 14,513,649 shares of the company’s stock valued at $1,886,872,000 after buying an additional 237,973 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Johnson & Johnson by 4.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 12,576,360 shares of the company’s stock valued at $1,757,159,000 after buying an additional 551,632 shares during the period. Fisher Asset Management LLC increased its stake in shares of Johnson & Johnson by 2.8% during the fourth quarter. Fisher Asset Management LLC now owns 12,127,379 shares of the company’s stock valued at $1,694,437,000 after buying an additional 329,705 shares during the period. Finally, Swiss National Bank increased its stake in shares of Johnson & Johnson by 0.4% during the third quarter. Swiss National Bank now owns 10,778,264 shares of the company’s stock valued at $1,401,282,000 after buying an additional 39,800 shares during the period. Institutional investors and hedge funds own 67.40% of the company’s stock.

Several brokerages have recently commented on JNJ. Citigroup cut their price target on Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating on the stock in a research note on Monday, April 23rd. Credit Suisse Group cut their price target on Johnson & Johnson from $154.00 to $151.00 and set an “outperform” rating on the stock in a research note on Friday, April 20th. Wells Fargo restated an “outperform” rating and set a $150.00 price target (down previously from $160.00) on shares of Johnson & Johnson in a research note on Wednesday, April 18th. Stifel Nicolaus cut their price target on Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Wednesday, April 18th. Finally, Leerink Swann restated an “outperform” rating and set a $160.00 price target (down previously from $175.00) on shares of Johnson & Johnson in a research note on Wednesday, April 18th. They noted that the move was a valuation call. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $142.23.

Johnson & Johnson opened at $123.85 on Friday, according to Marketbeat Ratings. Johnson & Johnson has a 1 year low of $125.00 and a 1 year high of $125.73. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.58. The stock has a market capitalization of $335.71 billion, a price-to-earnings ratio of 16.97, a P/E/G ratio of 1.92 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The company had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. During the same quarter in the previous year, the firm earned $1.83 earnings per share. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 8.13 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th will be paid a dividend of $0.90 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.91%. Johnson & Johnson’s payout ratio is presently 46.03%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply